Levetiracetam Tablet, Film Coated
Product Images NDC 55154-5699

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55154-5699). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Formula Calculation For Patients With Renal Impairment (A518c4f5 8b66 4770 B971 3534d581ca99 02)

Formula Calculation For Patients With Renal Impairment (A518c4f5 8b66 4770 B971 3534d581ca99 02)
This text provides a formula for calculating the appropriate weight in kilograms for an individual based on their age in years. It also gives a correction factor for female patients. Additionally, it includes a measurement for serum creatinine in milligrams per deciliter.*
FDA Label Image

Then Clcr Is Adjusted For Body Surface Area (bsa) As Follows (A518c4f5 8b66 4770 B971 3534d581ca99 03)

Then Clcr Is Adjusted For Body Surface Area (bsa) As Follows (A518c4f5 8b66 4770 B971 3534d581ca99 03)
FDA Label Image

Levetiracetam Structural Formula (A518c4f5 8b66 4770 B971 3534d581ca99 04)

Levetiracetam Structural Formula (A518c4f5 8b66 4770 B971 3534d581ca99 04)
FDA Label Image

B00f2ee7 8be3 4007 Ae9e 38060f5ec377 00

B00f2ee7 8be3 4007 Ae9e 38060f5ec377 00
FDA Label Image

Levetiracetam Oral Solution Weight-based Dosing Calculation For Pediatric Patients (Image 01)

Levetiracetam Oral Solution Weight-based Dosing Calculation For Pediatric Patients (Image 01)
FDA Label Image

Figure 1: Responder Rate (≥ 50% Reduction From Baseline) In Study 1 (Image 02)

Figure 1: Responder Rate (≥ 50% Reduction From Baseline) In Study 1 (Image 02)
FDA Label Image

Figure 3: Responder Rate (≥ 50% Reduction From Baseline) In Study 3 (Image 03)

Figure 3: Responder Rate (≥ 50% Reduction From Baseline) In Study 3 (Image 03)
FDA Label Image

Figure 2: Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A (Image 04)

Figure 2: Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A (Image 04)
The text provided shows the percentage of patients that were involved in a study, which was 39.4%. The study compared the results of a new drug with a placebo, and the group that received the drug experienced statistically significant results compared to the placebo group. The text does not provide any further information about the drug or study, and it is not clear what "109" refers to.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Image 05)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Image 05)
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Image 06)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Image 06)
This text appears to be a statistical result of a clinical trial for a medication called "Lovctrsctam Tabis." The trial found that the medication had a success rate of 81%, which was deemed statistically significant when compared to a placebo. The text also includes a percentage of 19.6%, but it is unclear what this refers to.*
FDA Label Image

Figure 6: Responder Rate (≥ 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Image 07)

Figure 6: Responder Rate (≥ 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Image 07)
The text appears to be a mixture of gibberish, therefore I cannot generate a meaningful description. It seems to be a result of poor quality in scanning.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.